Allergan Aesthetics to expand body contouring portfolio with Soliton acquisition

Soliton and its rapid acoustic pulse device Resonic will be acquired by Allergan Aesthetics, the companies announced in a press release.

The definitive agreement reached between Allergan Aesthetics, an AbbVie company, and Soliton will expand the former’s body contouring treatment portfolio by adding Resonic, which recently received 510(K) clearance from the FDA.

“There is a huge unmet need to address cellulite, and effective treatments have been elusive and frustrating for consumers,” Carrie Strom, president, Global Allergan Aesthetics, and senior vice president, AbbVie, said in the release. “Soliton’s technology offers a new, completely noninvasive approach with clinically proven results to reduce the appearance of cellulite with no patient downtime. The addition of this technology complements Allergan Aesthetics’ portfolio of body contouring treatments. Health care providers will now have another option to address consumers’ aesthetic concerns.”

Allergan Aesthetics will pay $22.60 in cash for each share of Soliton, according to terms of the agreement. The transaction is valued at approximately $550 million and is subject to closing conditions and clearance by U.S. antitrust authorities, according to the release.